Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with one of the worst prognoses worldwide and has an overall 5-year survival rate of only 9%. Although chemotherapy is the recommended treatment for patients with advanced PDAC, its efficacy is not satisfactory. The dense dysplastic stroma of PDAC is a major obstacle to the delivery of chemotherapy drugs and plays an important role in the progression of PDAC. Therefore, stroma-targeting therapy is considered a potential treatment strategy to improve the efficacy of chemotherapy and patient survival. While several preclinical studies have shown encouraging results, the anti-tumor potential of the PDAC stroma has also been revealed, and the extreme depletion might promote tumor progression and undermine patient survival. Therefore, achieving a balance between stromal abundance and depletion might be the further of stroma-targeting therapy. This review summarized the current progress of stroma-targeting therapy in PDAC and discussed the double-edged sword of its therapeutic effects.

Keywords: pancreatic ductal adenocarcinoma, stroma, chemotherapy, tumor microenvironment, nanotherapy

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) ranks seventh as the cause of cancer-associated mortality worldwide and has an overall 5-year survival rate of only 9% (1, 2). In the United States, PDAC is projected to become the second deadliest cancer by 2030 (3). With the acceleration of industrialization and population aging, the incidence of PDAC has also increased in China (4). In the past few decades, the treatment of PDAC has not made substantial progress. Surgery remains the only treatment that might achieve a cure. However, about 80% of PDAC patients are unable to access surgery at the time of diagnosis (5). Because of the early recurrence and metastasis of PDAC, even the patients who have already undergone radical surgery present a 5-year survival rate of only 25% (5). Therefore, PDAC has emerged as a major public health problem that needs to be addressed urgently.

For the majority of patients with advanced PDAC, chemotherapy is the generally recommended treatment. The standardized chemotherapy regimens include the use of the cytotoxic nucleoside analog gemcitabine or a more potent but highly toxic four-drugs regimen, FOLFIRINOX (i.e., 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) (6). In addition, chemotherapy is also applied as a neoadjuvant treatment for some PDAC patients who are suitable for surgery to lower the risk of
recurrence (7). However, the efficacy of these regimens is not satisfactory. One of the main features of PDAC is its dense abundant stroma, which increases the interstitial fluid pressure (IFP). The compression of intratumoral vasculature impedes the efficiency of chemotherapeutic agent delivery and forms a hypoxic microenvironment, which promotes tumor progression (8, 9). Therefore, reversing the negative effects of PDAC stroma might improve the efficacy of chemotherapy and patient survival (8).

**PDAC Stroma and Its Role in Disease Progression**

In PDAC, tumor cells account for less than 20% of the total tumor volume, while the stroma components occupy more than 70% (10). The dense desmoplasia stroma of PDAC consists of several cellular components (e.g., fibroblasts, stellate cells, immune cells, and pericytes), acellular components (e.g., fibrin, collagen, hyaluronic acid, fibronectin, growth factors, and cytokines), and biophysical components (e.g., low pH, hypoxia, and high tumor IFP) (11). These components interact mutually to promote the progression of PDAC (12).

During the progression of PDAC, pro-inflammatory cytokines secreted by neoplastic cells stimulate fibroblasts and pancreatic stellate cells (PSCs), which produce extracellular matrix (ECM) and increase fibrotic stromal deposition (13, 14). The solid stress generated by the dense stroma and lymphatic obstruction causes intratumoral IFP to increase, which leads to vascular compression, tissue perfusion reduction, and a hypoxic microenvironment (15, 16). In fact, approximately 80% of intratumoral blood vessels are dysfunctional, poorly fenestrated, and covered with a thick layer of pericytes, which hinder the effective accumulation of chemotherapeutic agents. In addition, the PDAC stroma potentially alters the pharmacokinetics and pharmacodynamics of chemotherapeutic drugs (8). For example, the high expression level of cytidine deaminase in the stroma shortened the circulating half-life of gemcitabine (17). Furthermore, the fibrotic microenvironment of PDAC results in an inhibitory effect on the innate and adaptive immune systems, reducing cytotoxic T cells and increasing M2 macrophages, N2 neutrophils, and T-regulatory cells (Tregs) at tumor sites. Growth factors and cytokines secreted by PSCs also promote the formation of a tumor immunosuppressive microenvironment (18). In summary, the dense proliferative stroma of PDAC promotes tumor progression and metastasis via various routes (11). Therefore, overcoming the tumor-promoting effects of PDAC stromal barriers has become an imperative issue.

**STROMA-TARGETING THERAPY IN PDAC**

In order to overcome the physical and biological barriers to effective PDAC treatments, several strategies based on targeting the stroma have been designed to improve the efficacy of chemotherapeutic agents and reverse the stroma’s impact on tumor progression (Table 1).

### Depletion of the Stroma in PDAC

One of the main components of PDAC stroma is hyaluronic acid (HA) or hyaluronan (Figure 1). HA is a complex glycosaminoglycan secreted abundantly by neoplastic cells (19–21), and it is a core polymer in the assembly of multiple hydrophilic matrix proteoglycans (22). HA binds to cell surface receptors to maintain tumor cell survival and activate downstream signaling pathways related to tumor proliferation, migration, and invasion (23–25). In addition, its ability to absorb and retain water increases IFP (24, 26). Therefore, HA is considered a potential therapeutic target in PDAC. Pegylated hyaluronidase (PEGPH20) is a pegylated nanoscale complex of recombinant human hyaluronidase (27, 28). Previous studies showed that PEGPH20 induced the degradation of HA, remodeled tumor vasculature, and improved chemotherapeutic drug efficacy (22, 27, 29). A phase II clinical study HALO-109-202 (NCT01839487), involving 279 patients with metastatic PDAC, showed that PEGPH20 combined with Abraxane (an albumin-bound paclitaxel nanocomplex) and gemcitabine nearly doubled the progression-free survival and improved the overall survival in patients with high level HA (30). However, a subsequent phase III clinical study HALO-109-301 (NCT02715804) showed that PEGPH20 combined with Abraxane and gemcitabine did not significantly extend the overall survival of PDAC patients. Therefore, Halozyme announced the termination of further research and development of PEGPH20 in November 2019.

Another major component of the tumor ECM is collagen (Figure 1). PDAC stroma is rich in fibrillar collagens, which support tumor cell survival and promote tumor progression through discoidin domain receptor 1 and 2 (DDR1 and 2). High expression of DDR1 was identified as an independent risk factor for poor prognosis in patients with PDAC (31). In fact, the selective small molecule inhibitor of DDR1 reduced collagen deposition and improved the response to chemotherapy in PDAC mouse models (32). Preclinical studies are currently investigating the effects of DDR1 inhibition on the immune microenvironment of PDAC. Recently, the potent antifibrotic ability of halofuginone (a natural quinazolinone alkaloid febrifugine analog) was observed in a genetically engineered mouse model of PDAC (33). Halofuginone directly inhibited the activation of PSCs, thereby reducing the deposition of several ECM components, including collagen and HA. The decrease of the intratumoral IFP resulted in the improved delivery of chemotherapeutic agents, which was visually proven by exploiting the autofluorescence of doxorubicin. In addition, halofuginone helped increase immune cell infiltration and shift them closer to cytokeratin positive tumor cells, suggesting that stroma-targeting therapy might improve the efficacy of immunotherapy to some extent in PDAC.

The Hedgehog (Hh) signaling pathway is generally hyperactive in PDAC (Figure 1) (34). It is known that the Hh signaling pathway activates PSCs through paracrine effects and regulates stroma deposition (35). There are several strategies intended to treat PDAC by inhibiting the Hh signaling pathway in order to eliminate the tumor stroma (36). Cycloamine is a natural steroidal alkaloid that inhibits the Hh signaling pathway via binding to Smoothened (SMO) (37). It reduced fibronectin content and enhanced tumor vascularization in a PDAC xenograft model.
TABLE 1 | Clinical trials assessing stroma-targeting therapy in PDAC.

| Target | Agents | Patient population | Trial phase | mPFS (months) | mOS (months) | Status | NIH number |
|--------|--------|---------------------|-------------|---------------|--------------|--------|------------|
| HA | PEGPH20 + GEM + nab-paclitaxel vs GEM + nab-paclitaxel | Metastatic PDAC | Phase II | 6.0 vs 5.3 | 9.6 vs 9.2 | Completed | NCT0189487 |
| Hedgehog | IPI-926 | Solid tumors (including PDAC) | Phase I | – | – | Completed | NCT00761696 |
| CTGF | Pamrevlumab + GEM + nab-paclitaxel vs GEM + nab-paclitaxel | Locally advanced PDAC | Phase I/ II | – | – | Completed | NCT02210559 |
| R-A system | Losartan + FOLFIRINOX + chemotherapy | Locally advanced PDAC | Phase II | 4.3 | 9.4 | Completed | NCT01181245 |

CTGF, connective tissue growth factor; DDR1, discoidin domain receptor 1; FOLFIRINOX, 5-fluourouracil, leucovorin, oxaliplatin, and irinotecan; GEM, gemcitabine; HA, hyaluronic acid; NIH, National Institutes of Health; mOS, median overall survival; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; mPFS, median progression-free survival; R-A system, renin-angiotensin system; SBRT, stereotactic body radiation therapy; UM, ultrasound microbubbles.

mouse model. When combined with paclitaxel-loaded nanoparticles, cyclopamine increased tumor growth inhibition by 63.3% (38). In addition, a preclinical study showed that IPI-926, a small molecule that inhibited the Hh pathway, increased blood vessel density and gemcitabine drug concentration in PDAC (39). In a phase I clinical trial, IPI-926 was well tolerated by PDAC patients (40). However, a phase II clinical trial of IPI-926 failed to show significant therapeutic benefits in PDAC patients (41, 42). Similarly, Vismodegib, another Hh pathway inhibitor, combined with gemcitabine did not significantly improve the median overall survival and progression-free survival in patients with metastatic PDAC compared with gemcitabine alone (43). In fact, while several treatments targeting the Hh signaling pathway showed uplifting results in preclinical models (44), few of them improved patient survival, and their use was often accompanied by drug-related toxicity (45). In addition to the above-mentioned drugs, other stroma-targeting drugs include metalloproteinase inhibitors (46–48), connective tissue growth factor (CTGF) antagonists (e.g., pamrevlumab) (49, 50), and anti-fibrotic agents (e.g., pirfenidone) (Figure 1) (51, 52).

**Remodeling Tumor Vasculature**

The dense fibrotic stroma surrounding the blood vessels and the proliferating cancer-associated fibroblasts (CAFs) damage intratumoral vasculature, resulting in a hypoxic microenvironment, which promotes PDAC invasion, metastasis, and the acquisition of chemoresistance phenotypes (Figure 1) (53–55). Therefore, remodeling PDAC blood vessels not only improves drug delivery but also overcomes the hypoxic microenvironment.

The transforming growth factor-β (TGF-β) signaling pathway is involved in the adhesion of pericytes to tumor vascular endothelial cells (56). TGF-β receptor kinase inhibitors or monoclonal antibodies enhanced vascular access and promoted the perfusion of chemotherapeutic agents to PDAC tumor sites (56–58). In addition, the repurposing of antihypertensive drugs targeting the renin-angiotensin pathway can reprogram CAFs toward normalizing ECM by inhibiting TGF-β (59, 60). In tumors, Angiotensin II (Ang II) activates the renin-angiotensin system (R-A system), which promotes CAFs to express CTGF by binding to Ang II receptors (59, 60). In tumors, Angiotensin II (Ang II) activates the R-A system, which promotes CAFs to express CTGF by binding to Ang II receptors (59, 60). In tumors, Angiotensin II (Ang II) activates the R-A system, which promotes CAFs to express CTGF by binding to Ang II receptors (59, 60). In tumors, Angiotensin II (Ang II) activates the R-A system, which promotes CAFs to express CTGF by binding to Ang II receptors (59, 60). In tumors, Angiotensin II (Ang II) activates the R-A system, which promotes CAFs to express CTGF by binding to Ang II receptors (59, 60). In tumors, Angiotensin II (Ang II) activates the R-A system, which promotes CAFs to express CTGF by binding to Ang II receptors (59, 60).
Angiotensin II type 2 receptor (AT2R) in pancreatic fibroblasts also leads to tumor cell proliferation (65). Therefore, the role of the Ang II signaling pathway in the PDAC stroma needs to be further investigated before its use in the clinic.

In addition to the pharmacological interference, focused ultrasound combined with microbubbles was investigated to determine if it improved vascular patency. Microbubbles are restrained within the vascular compartment because of their diameter. Focused ultrasound causes the microbubbles to disintegrate, which releases acoustic forces that are capable of inducing thrombolysis and increasing drug penetration (66). Moreover, appropriate ultrasound energy induces the destruction of the microbubbles and generates acoustic pressure that temporarily increases the permeability of blood vessels and cell membranes (66). The efficacy of ultrasound microbubble delivery of gemcitabine was evaluated in a PDAC murine model. The study showed that the ultrasound microbubbles treatment group presented significant tumor growth inhibition (67). In addition, the use of nab-paclitaxel combined with ultrasound microbubbles significantly inhibited the activity of PDAC tumor cells in vitro and reduced the tumor volume in a subcutaneous PDAC mouse model (68). Furthermore, a clinical trial evaluated the efficacy of focused ultrasound combined with microbubble delivery of gemcitabine in PDAC patients. The combination-treated patients tolerated more gemcitabine chemotherapeutic cycles, and half of them showed maximum tumor diameter decrease. In addition, the median survival was prolonged by 8.7 months (69).

**Nano-Drug Delivery Systems in PDAC**

The dense stroma of PDAC limits the application of chemotherapeutic drugs to efficiently target neoplastic cells through the enhanced permeability and retention (EPR) effect (15, 70). Nanomedicine, the result of the formulation of drugs into nano-size delivery carriers, such as liposomes and polymer nanoparticles, delivers chemotherapeutic agents through mechanisms that are different from those used to deliver conventional non-encapsulated molecular drugs (71). By optimizing the particle size, surface charge, and specific ligand modification of nanocarriers, nanomedicine improves the ability of nanocarriers to penetrate the stromal barrier in PDAC tumor sites (72). A study showed that both 30-nm and 100-nm nanoparticles penetrated into the hyperpermeable colon cancer model, but only the 30-nm nanoparticle penetrated the stroma-rich PDAC model and achieved anti-tumor efficacy in the murine model (73). Different charges on ECM components make the nano-drug delivery heterogeneous in spatial...
distribution, compromising the drug delivery efficiency (74). Therefore, active targeted drug delivery with modified specific ligands has been designed to address the issues (75, 76). Several studies showed that nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) improved the delivery efficiency of paclitaxel. In addition, nab-paclitaxel combined with gemcitabine improved the overall survival and disease-free survival in patients with advanced PDAC (77), and this combination therapy strategy has been approved by the Food and Drug Administration (FDA). Several nab-paclitaxel-based combination therapy strategies are currently in the clinical evaluation stage (78, 79). A recent meta-analysis showed that nanoparticles improved the efficacy of various anti-tumor drugs while reducing their toxicity in patients with PDAC (80).

To further improve the efficiency of nano-delivery drugs, smart nanoparticles have been designed to respond to environmental or external stimuli, which triggers drug release after passive or active tumor accumulation (81). The PDAC tumor microenvironment exhibits some unique physiological characteristics, such as the low pH, cancer cells lysosomes (81), and a high level of reducing substances in tumor cells (e.g., glutathione) (82). Therefore, a nano-drug delivery system responsive to the stimuli from the internal environment of the tumor has been designed. In addition, researchers have also designed nano-drug delivery systems triggered by the external stimuli. Thermal, magnetic, and mechanical waves (including ultrasound) via image guidance have been applied to trigger the nano-drug delivery system to release the loaded drug. Furthermore, a study combined the internal and external stimuli and designed a new nano-drug carrier to respond to a three-dimensional trigger (ultrasonic, acid-sensitivity and reduced glutathione) (Figure 1) (83).

STROMA-TARGETING THERAPY AS A DOUBLE-EDGED SWORD

The tumor suppressive properties of the PDAC stroma have been revealed gradually. Several studies, using genetic or pharmacological approaches to eliminate the PDAC stroma in preclinical models, showed that stromal depletion promoted tumor cell proliferation, invasion, and metastasis and reduced survival (84, 85). PDAC tumor cells in the primary lesion showed loss of differentiation, epithelial-to-mesenchymal transition (EMT), and enhanced cancer stem cell-like phenotypes after stromal ablative treatment. In addition, severe weight loss, acidosis, and cachexia were observed in PDAC mouse models (84–87). These findings suggest that stroma depletion might activate dormant neoplastic cells and induce their metastatic potential, thereby promoting PDAC progression.

Prominently, different subtypes of CAFs that exhibit distinct characteristics and activity levels have been identified in breast cancer (88) and PDAC (89). In PDAC, CAFs have been classified into several subpopulations on the basis of the expression patterns of various fibroblast markers (89, 90). One subgroup is characterized by the α-SMA expression and generally considered as myofibroblastic CAFs, while another is classified as inflammatory CAFs for the secretion of multiple inflammatory chemokines (e.g., IL-6). Studies have assessed the effects of these CAFs subgroups on tumor microenvironment and immune escape in PDAC. For example, the targeted inhibition of IL-6, which is produced by inflammatory CAFs, improved the efficacy of anti-PD-L1 checkpoint inhibitors in PDAC. However, the genetic deletion of Hedgehog resulted in the reduction of stroma deposition and myofibroblastic CAFs, inducing more aggressive and de-differentiated tumor phenotypes (85). Similarly, another study determined that genetic deletion of myofibroblastic CAFs induced more aggressive PDAC tumor phenotypes, manifested by EMT, cancer stemness, chemotherapy resistance, and tumor immune evasion (84). These findings suggest that inflammatory CAFs might be the potential therapeutic target, while myofibroblastic CAFs support tumor suppression in PDAC. Recently, Biffi et al. identified that TGFβ and interleukin 1 (IL1) as tumor-secreted ligands promoted CAFs heterogeneity, illuminating strategies to selectively target CAFs that support tumor growth (91).

Pericyte is an important cellular component related to the tumor vasculature in PDAC (92). One of the main biomarkers associated with vascular pericytes is platelet-derived growth factor receptor-β (PDGFR-β) (93). Its ligand, PDGF, was shown to induce pericyte-fibroblastic transition (PFT), which makes pericyte an origin of CAFs, thereby promoting tumor invasion and metastasis. Pharmacological inhibition and genetic deletion of PDGFR-β reversed PDGF induced PFT (92). However, PDGFR-β inhibitors (e.g., imatinib and sunitinib) caused pericytes to detach from vascular endothelial cells, destroying vasculature integrity and promoting tumor metastasis (93). Therefore, non-discriminatory depletion of CAFs might remove partial tumor-suppressing CAFs subgroups. Although stroma-targeting therapy enhances the delivery of chemotherapeutic agents, it might also promote tumor chemo-resistance and metastasis. In fact, the unsatisfactory results in clinical applications and the revelation that the PDAC stroma harbors tumor suppressive activity indicates that future research should focus on the tumor ECM biology. The various components in the PDAC stroma might have different effects on tumor biological behavior. Therefore, the pathophysiological analysis of distinct PDAC stromal cell might enlighten future stroma-targeting strategies (90).

DISCUSSION AND PERSPECTIVE

The dense desmoplasia stroma of PDAC, which hinders the efficient delivery of chemotherapeutic agents, plays a critical role in tumor progression and metastasis. On the one hand, various stroma-targeting treatment strategies have been applied to improve drug efficacy and inhibit tumor progression. However, the clinical efficacy of these treatments has not been satisfactory in PDAC patients. On the other hand, several studies showed that extreme PDAC stromal depletion caused a deterioration in tumor phenotypes, supporting the perspective that the stromal response is a host response to inhibit tumor growth. Therefore, a stroma-targeting treatment might not be an optimal neoadjuvant therapy for patients with locally advanced PDAC.
It is worth noting that lack of taking the heterogeneity of PDAC stromal composition into account might be one reason why unsatisfactory results were observed in the clinical studies. Stroma-targeting therapy would be beneficial in sites with high density of the targeted stromal composition, while be a disadvantage in sites with low density. Therefore, it is crucial to access the quantitative degree and type of tumor stroma density (TSD), which might be a significant section of the clinical study design (94). The phase II study, HALO-109-202, was an example of stratification analysis based on the level of HA (30). In addition, the activation status of stroma could be identified, according to consensus clustering of expression levels of certain biomarkers (95). For instance, prior work found that A Disintegrin And Metalloproteases 12 (ADAM12) was a blood-borne proxy for stromal activation, the levels of which had prognostic significance and correlate with treatment benefit (96). In fact, the stroma is a reservoir of various potential biomarkers, which might be used to classify PDAC patient subgroups and facilitate the clinical application of stroma-targeting therapy.

In addition, the heterogeneity of stromal microenvironment between the primary tumor and metastases sites might result in distinct responses to stroma-targeting therapy (94). Previous studies showed that PDAC metastatic tumors had limited driver-mutation heterogeneity compared to the primary tumors (97), and TSD was various across metastatic sites and primary tumors (94). These observations suggested that the heterogeneity of stroma might be a function of host organ-site physiology and not inferior to cancer genomic or epigenomic variations between the primary and metastatic tumors. Furthermore, the effects of individual and ethnic-specific genetic variations on the stroma microenvironment of PDAC might need further investigation. Genomic analyses of single PDAC stroma cell might help identify inter- and intra-individual heterogeneity and optimize individualized stroma-targeting therapy in order to maximize patient treatment benefits (98–100).

Pharmacological agents that alter the tumor microenvironment might help evade the negative effect of stromal depletion. For example, the inhibition of PDAC tumor-associated macrophages by clodronate liposomes prevented the establishment of a pre-metastatic microenvironment in organs of metastasis, markedly reducing metastasis formation (101). Therefore, clodronate liposomes might be a candidate for combination strategies with stroma-targeting therapy. Furthermore, although the proliferative stroma of PDAC usually exerts an immunosuppressive effect, stromal depletion might exacerbate the immunosuppression effect in some cases (84). Therefore, the combination of immune checkpoint inhibitors and stroma-targeting therapy might reduce the negative effects of stromal ablation and further enhance the efficacy of chemotherapy in PDAC patients.

In summary, stroma-targeting therapy in PDAC has emerged as a double-edged sword. On the one hand, it enhances the delivery of chemotherapeutic agents to tumor sites. On the other hand, it eliminates the physical and biochemical barriers that potentially inhibit tumor progression. Therefore, it is imperative to understand the complex role of the PDAC stroma in order to improve the current stroma-targeting therapies through appropriately adjusting the balance between stroma deposition and ablation.

**REFERENCES**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin (2015) 65(2):87–108. doi: 10.3322/caac.21262
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin (2019) 69(1):7–34. doi: 10.3322/caac.21551
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res (2014) 74(11):2913–21. doi: 10.1158/0008-5472.CAN-14-0155
4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin (2016) 66(2):115–32. doi: 10.3322/caac.21338
5. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet (2016) 388(10039):73–85. doi: 10.1016/S0140-6736(16)00141-0
6. Conroy T, Hammel P, Hebbu M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med (2018) 379(25):2395–406. doi: 10.1056/NEJMoa1809775
7. Maeda S, Unno M, Yu J. Adjuvant and neoadjuvant therapy for pancreatic cancer. J Pancreatol (2019) 2(3):100–6. doi: 10.1097/PJ9.0000000000000028
8. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol (2012) 9(8):454–67. doi: 10.1038/nrgastro.2012.115
9. Dougan SK. The Pancreatic Cancer Microenvironment. Cancer J (2017) 23(6):321–5. doi: 10.1097/PPO.0000000000000288

**AUTHOR CONTRIBUTIONS**

BJ and JG managed the study design. BJ, JL, and YW conducted the literature search. CL performed the data extraction. BJ drafted the manuscript. LZ, LY, and JG reviewed the manuscript and made critical revisions for important intellectual content. JG provided funding support. All authors contributed to the article and approved the submitted version.

**FUNDING**

The present study was supported by the National Natural Science Foundation of China (Grant No. 81972324) and the China Academy of Medical Sciences Innovation Fund for Medical Sciences (Grant No. 2016-I2M-3-019).

**ACKNOWLEDGMENTS**

We thank Nicole Clarke, PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.
Soehn S, Engeland K. RHAMM is differentially expressed in the cell cycle and
22. Thompson CB, Shepard HM, O Connor PM, Kadhim S, Jiang P, Osgood RJ, et al. Enzymatic deactivation of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther (2010) 9(11):3052–64. doi: 10.1158/1535-7163.MCT-10-0470
23. Sohr S, Engeland K. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle (2008) 7(21):3448–53. doi: 10.4161/cc.7.21.10704
24. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer (2006) 6(8):583–92. doi: 10.1038/nrc1893
25. Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol (2008) 18(4):244–50. doi: 10.1016/j.semcancer.2008.03.009
26. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreatic cancer. Br J Cancer (2013) 108(1):1–8. doi: 10.1038/bjc.2012.569
27. Jacobetz MA, Chan DS, Neese A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2013) 62(1):112–20. doi: 10.1136/gutjnl-2012-302529
28. Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost GI, et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther (2015) 14(2):523–32. doi: 10.1158/1535-7163.MCT-14-0580
29. Whatcott CJ, Han H, Von Hoff DD. Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. Cancer J (2015) 21(4):299–306. doi: 10.1097/PPO.0000000000001410
30. Hingorani SR, Zheng L, Bullock AL, Seery TE, Harris WP, Sigal DS, et al. HALLO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol (2018) 36(4):359–66. doi: 10.1200/JCO.2017.74.9564
31. Huo Y, Yang M, Liu W, Yang J, Fu X, Liu D, et al. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res (2015) 34(1):88– doi: 10.1186/s13046-015-0202-1
32. Aguilera KY, Huang H, Du W, Hagopian MM, Wang Z, Hinz S, et al. Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigeniciy in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther (2017) 16(11):2473–85. doi: 10.1158/1535-7163.MCT-16-0834
33. Elahi-Gedvilo KY, Carlson M, Zettervall J, Provenzano PP. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. Cancer Res (2019) 79(2):372–86. doi: 10.1158/0008-5472.CAN-18-1334
34. Rucki AA, Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol (2014) 20(9):2237–46. doi: 10.3748/wjg.v20.i9.2237
35. Youch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, et al. A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 455(7211):406–10. doi: 10.1038/nature07275
36. Onishi H, Katano M. Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J Gastroenterol (2014) 20(9):3235–42. doi: 10.3748/wjg.v20.i9.2335
37. Heretsch P, Tzagkaroulaki L, Giannis A. Cyclopamine and hedgehog signaling; chemistry, medical biology, preliminary aspects. Angew Chem Int Ed Engl (2010) 49(20):3419–23. doi: 10.1002/anie.201000073
38. Zhang B, Jiang T, Shen S, She X, Tuo Y, Hu Y, et al. Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer. Biomaterials (2016) 103:12–21. doi: 10.1016/j.biomaterials.2016.06.048
39. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science (2009) 324(5933):1457–61. doi: 10.1126/science.1171362
40. Jimeno A, Weiss GI, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, et al. Phase I Study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res (2013) 19(10):2766–74. doi: 10.1158/1078-0432.CCR-12-3654
41. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med (2013) 19(11):1410–22. doi: 10.1038/nm.3389
42. Infinity Pharmaceuticals. Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. Available at: http://www.businesswire.com/news/home/2012070500146/en/Infinity-Reports-Update-Phase-2-Study-Saridegib-Vg2AsUGJMQM
43. Catenacci DV, Juntilla MR, Karrin T, Bahary N, Horiba MN, Nattam SR, et al. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol (2015) 33(36):4284–92. doi: 10.1200/JCO.2015.62.8719
44. Feldmann G, Dhara S, Vendich V, Bedja D, Beatty R, Mullendore M, et al. Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers. Cancer Res (2007) 67(5):1878–96. doi: 10.1158/0008-5472.CAN-06-3281
45. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas (2016) 45(3):370–5. doi: 10.1097/MPA.0000000000001458
46. Bramhall SR, Rosemurgy A, Brown PD, Bowey C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol (2001) 19(15):3447–55. doi: 10.1200/JCO.2001.19.15.3447
47. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Bailleit M, Buckels JAC. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 87(2):161–7. doi: 10.1038/sj.bjc.6600446
48. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor
BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2003) 21(17):3296–302. doi: 10.1200/JCO.2003.02.0998

49. Neesse A, Frese KK, Rapido TE, Nakagawa T, Sternlicht MD, Seely EW, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreatic cancer. Proc Natl Acad Sci U S A (2013) 110(13):12325–30. doi: 10.1073/pnas.1300415110

50. Jichi H, Chiyil A, Gorska AE, Aakre ME, Bierie B, Tada M, et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 121(10):4106–17. doi: 10.1172/JCI47274

51. Koizumi S, Ohuchida K, Eguchi D, Ikenna N, Fujukawa K, Cui L, et al. Pten inhibition induces pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res (2013) 73(7):2345–56. doi: 10.1158/0008-5472.CAN-12-3180

52. Ji T, Li S, Zhang Y, Zhao X, et al. An MMP-2 Responsive Liposome Integrating Antibifosphen and Chemotherapy Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer. ACS Appl Mater Interfaces (2016) 8(5):3438–45. doi: 10.1021/acsami.5b11619

53. Erkan M, Reiser-Erkan C, Michalski CW, Deucke R, Sauliunaita D, Streit S, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia (2009) 11(5):497–508. doi: 10.1093/neo.81618

54. Guillemont F, Jovéanna JL, Vasseur S. Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways. Arch Biochem Biophys (2014) 545:69–73. doi: 10.1016/j.abb.2013.12.019

55. Bailey KM, Cornnell HH, Ibrahim-Hashim A, Wojtkowiak JW, Hart CP, Zhang X, et al. Evaluation of the “stein” phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer. PLoS One (2014) 9(12):e113586. doi: 10.1371/journal.pone.0113586

60. Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, et al. Inhibiting the angiotensin II type I receptor blocker olmesartan inhibits the growth of The angiotensin II promotes the proliferation of activated pancreatic stellate cells. Scand J Gastroenterol (2006) 340(3):742

66. Chauhan VP, Martin JD, Seely EW, Nakagawa T, Sternlicht MD, Seely EW, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreatic cancer. Proc Natl Acad Sci U S A (2013) 110(13):12325–30. doi: 10.1073/pnas.1300415110

57. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, et al. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res (2013) 73(7):2345–56. doi: 10.1158/0008-5472.CAN-12-3180

58. Hama K, Ohnishi H, Yasuda H, Ueda N, Mashima H, Satoh Y, et al. Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer Treatment: Implications for immunotherapy. J Control Release (2012) 153(1):13–20. doi: 10.1016/j.jconrel.2011.09.007

59. Hama K, Ohnishi H, Aoki H, Kita H, Yamamoto H, Osawa H, et al. Angiotensin II type 2 receptor signaling signiﬁcantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer (2010) 10:67. doi: 10.1186/1471-2407-10-67

60. Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl (2019) 98:1252–76. doi: 10.1016/j.msec.2019.01.066

61. Tanaka HY, Kano MR. Stomal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Sci (2018) 109(7):2085–92. doi: 10.1111/cas.13630

65. Ji T, Zhao Y, Ding Y, Nie G. Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. Adv Mater (2013) 25(26):3508–25. doi: 10.1002/adma.201300299

66. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 6(12):815–23. doi: 10.1038/nnano.2011.166

62. Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl (2019) 98:1252–76. doi: 10.1016/j.msec.2019.01.066

63. Stylianopoulos T, Jain RK. Design considerations for nanotherapeutics in oncology. Nanomed Nanotechnol Biol Med (2015) 11(8):1893–907. doi: 10.1016/j.nano.2015.07.015

64. Peer D, Karp JM, Hong S, Farokhzad OC, Marglit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 2(12):751–80. doi: 10.1038/nnano.2007.387

65. Bressand D, Novell A, Girault A, Raoul W, Fromont-Hankard G, Escoffe J-M, et al. Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model. Mol Pharm (2019) 16(9):3814–22. doi: 10.1021/acs.molpharmaceut.9b00416

66. Hoy SM. Albumin-bound paclitaxel: a review of its use for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol (2014) 8(7):739–47. doi: 10.1586/17474124.2014.927799

67. Lim SH, Kang K, Park SM, Jang JH, Park JH, Seo JE, et al. Phase 2 Clinical Trial. Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Neoadjuvant Therapy with FOLFIRINOX in Combination With Losartan jamaoncol.2019.0892

68. Kato M, Takahashi M, Kato K, Ito T, Iwakuma R, Takahashi Y, et al. Pancreatic ductal adenocarcinoma: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2003) 21(17):3296–302. doi: 10.1200/JCO.2003.02.0998
84. Özdemir BC, Pentecheva-Hoang T, Carstens JL, Zheng X, Wu C-C, Simpson TR, et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell (2015) 28(6):831–3. doi: 10.1016/j.ccell.2015.11.002
85. Rhim Andrew D, Oberstein Paul E, Thomas Dafydd H, Mirek Emily T, Palermo Carmine F, Sastra Stephen A, et al. Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell (2014) 25(6):735–47. doi: 10.1016/j.cccr.2014.04.021
86. Lee JJ, Perera RM, Wang H, Wu D-C, Liu XS, Han S, et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci U S A (2014) 111(30):E3091–E1000. doi: 10.1073/pnas.1411679111
87. Roberts KJ, Kershner AM, Beachy PA. The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy. Cancer Cell (2017) 32(4):404–10. doi: 10.1016/j.ccc.2017.08.007
88. Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell (2018) 33(3):463–79.e10. doi: 10.1016/j.ccell.2018.01.011
89. Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med (2017) 214(3):579–96. doi: 10.1084/jem.20162024
90. Elyada E, Bolintini M, Laise P, Flynn WF, Courtois ET, Burkhalter RA, et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov (2019) 9(8):1102–23. doi: 10.1158/2159-8290.CD-19-0094
91. Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Almeida AS, Ponz-Sarvise M, et al. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ, IL4, and IL13. J Exp Med (2016) 233(2):301.
92. Cooke VG, LeBluvs VS, Keskin D, Khan Z, O’Connell JT, Teng Y, et al. Pericyte death results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 21(1):66–81. doi: 10.1016/j.cccr.2011.11.024
93. Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, et al. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol (2018) 2018. doi: 10.1200/PO.17.00121
94. Moffitt RA, Maruyati R, Flate EL, Volmar KE, Loeca SGH, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet (2015) 47(10):1168–78. doi: 10.1038/ng.3398
95. Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, et al. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis (2018) 7(11):87. doi: 10.1038/s41389-018-0096-9
96. Makohon-Moore AP, Zhang M, Reiter JG, Bozic I, Allen B, Kundu D, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet (2017) 49(3):358–66. doi: 10.1038/ng.3764
97. Stachowiak P, Piccolo R, Blum Y, Cross J, Marisa L, Demetter P, et al. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology (2018) 155(6):1999–2013.e3. doi: 10.1053/j.gastro.2018.08.033
98. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature (2016) 531(7592):47–52. doi: 10.1038/nature16965
99. Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 518(7540):495–501. doi: 10.1038/nature14169
100. Grissmann H, Drezel C, Milosevic N, Sipos B, Rosenhale J, Gress TM, et al. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Gut (2017) 66(7):1278–85. doi: 10.1136/gutjnl-2015-310049

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Jiang, Zhou, Lu, Wang, Liu, You and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.